菜单

.Discovery_text_bottom_button::after {content: ”;position: absolute;bottom: 0;right: 0;border-right: 0.5rem solid #f4f8fb;border-left: 0.5rem solid transparent;border-top: 0.5rem solid transparent;border-bottom: 0.5rem solid #f4f8fb;}

.side-scroll {
position: relative;
top: 0;
overflow: hidden;
width: 100%;
/* height: 50vh; */
display: flex
;
}

.pannel .con{
height:auto
}

.Protein_text .col-sm-8 .text_ul_1 li {
position: relative !important;
padding-top: 0 !important;
padding-bottom: 0 !important;
border-top: none !important;
padding-left: 0.6rem !important;
}

.Protein_text .col-sm-8 .text_ul_1 li::after {
content: ” !important;
position: absolute !important;
top: 0.45rem !important;
left: 0 !important;
width: 0.20rem !important;
height: 2px !important;
border: none !important;
background: #9fb92e !important;
-webkit-transform: rotate(0) !important;
-moz-transform: rotate(0) !important;
-ms-transform: rotate(0) !important;
-o-transform: rotate(0) !important;
transform: rotate(0) !important;
}

#Protein img{
width:100%;
}

Versatile Single B Cell Technology for Multi-Species Antibody Discovery

WuXi Biologics’ single B cell screening platform is powered by Bruker’s Beacon Optofluidic technology. This cutting-edge platform enables rapid antibody discovery from a wide range of host species with high versatility and flexibility, supporting a broad spectrum of therapeutic targets.

 

  • Multiplexed, function-first screening of antibodies from human, mouse, rat, rabbit, camelid, chicken, and more
  • Ultra-high-throughput screening of over 20,000 primary B cells per day
  • Accelerated discovery with antibody sequences obtained in two weeks
  • High sequence recovery rate, with over 90% of recombinant antibodies retaining original binding and functional profiles after initial screening